Fluoxetine and neuroleptic malignant syndrome.
The authors present a case report of neuroleptic malignant syndrome (NMS) in a patient commencing treatment with fluoxetine alone who had previously been treated with several antipsychotic and antidepressant combinations. On reviewing the literature on the pathogenesis of NMS, the authors hypothesize a facilitative role of the neurotransmitter serotonin (5-HT) in conjunction with central dopaminergic blockade in the precipitation of NMS.
Halman
M
M
Department of Psychiatry, Toronto General Hospital, University of Toronto, Canada.
Goldbloom
D S
DS
D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004359:Drug Therapy, Combination; D005473:Fluoxetine / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology*; D009460:Neurologic Examination; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D012008:Recurrence
D005473:Fluoxetine